Sidwell R W, Huffman J H, Bailey K W, Wong M H, Nimrod A, Panet A
Institute for Antiviral Research, Utah State University, Logan 84322-5600, USA.
Antimicrob Agents Chemother. 1996 Nov;40(11):2626-31. doi: 10.1128/AAC.40.11.2626.
The oxygen free-radical scavenger recombinant human manganese superoxide dismutase (MnSOD) was studied for its effects on influenza virus infections in mice when used alone and in combination with ribavirin. Mice challenged with influenza A/NWS/33 (H1N1) virus were treated parenterally in doses of 25, 50, and 100 mg/kg of body weight per day every 8 h for 5 days beginning at 48 h post-virus exposure. An increase in mean day to death, lessened decline in arterial oxygen saturation, and reduced lung consolidation and lung virus titers occurred in the treated animals. To determine the influence of viral challenge, experiments were run in which mice were infected with a 100 or 75% lethal dose of virus and were treated intravenously once daily for 5 days beginning 96 h after virus exposure. Weak inhibition of the mortality rate was seen in mice receiving the high viral challenge, whereas significant inhibition occurred in the animals infected with the lower viral challenge, indicating that MnSOD effects are virus dose dependent. To determine if treatment with small-particle aerosol would render an antiviral effect, infected mice were treated by this route for 1 h daily for 5 days beginning 72 h after virus exposure. A dose-responsive disease inhibition was seen. An infection induced by influenza B/Hong Kong/5/72 virus in mice was mildly inhibited by intravenous MnSOD treatment as seen by increased mean day to death, lessened arterial oxygen saturation decline, and lowered lung consolidation. MnSOD was well tolerated in all experiments. A combination of MnSOD and ribavirin, each administered with small-particle aerosol, resulted in a generally mild improvement of the disease induced by the influenza A virus compared with use of either material alone.
研究了氧自由基清除剂重组人锰超氧化物歧化酶(MnSOD)单独使用以及与利巴韦林联合使用时对小鼠流感病毒感染的影响。用甲型流感病毒A/NWS/33(H1N1)攻击的小鼠,在病毒暴露后48小时开始,每8小时经肠胃外给予25、50和100mg/kg体重的剂量,持续5天。接受治疗的动物平均死亡天数增加,动脉血氧饱和度下降减轻,肺实变和肺病毒滴度降低。为了确定病毒攻击的影响,进行了实验,其中小鼠感染100%或75%致死剂量的病毒,并在病毒暴露后96小时开始每天静脉注射一次,持续5天。接受高剂量病毒攻击的小鼠死亡率受到微弱抑制,而感染低剂量病毒的动物则出现显著抑制,这表明MnSOD的作用具有病毒剂量依赖性。为了确定小颗粒气溶胶治疗是否具有抗病毒作用,感染的小鼠在病毒暴露后72小时开始,通过该途径每天治疗1小时,持续5天。观察到剂量反应性的疾病抑制作用。静脉注射MnSOD治疗轻度抑制了乙型流感病毒B/Hong Kong/5/72感染小鼠所引起的感染,表现为平均死亡天数增加、动脉血氧饱和度下降减轻以及肺实变减轻。在所有实验中,MnSOD的耐受性良好。与单独使用任何一种药物相比,MnSOD和利巴韦林均通过小颗粒气溶胶给药,联合使用后甲型流感病毒引起的疾病总体上有轻度改善。